492 related articles for article (PubMed ID: 11251172)
1. The anti-malarial artesunate is also active against cancer.
Efferth T; Dunstan H; Sauerbrey A; Miyachi H; Chitambar CR
Int J Oncol; 2001 Apr; 18(4):767-73. PubMed ID: 11251172
[TBL] [Abstract][Full Text] [Related]
2. Effects of artesunate on cytokinesis and G₂/M cell cycle progression of tumour cells and budding yeast.
Steinbrück L; Pereira G; Efferth T
Cancer Genomics Proteomics; 2010; 7(6):337-46. PubMed ID: 21156967
[TBL] [Abstract][Full Text] [Related]
3. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.
Efferth T; Giaisi M; Merling A; Krammer PH; Li-Weber M
PLoS One; 2007 Aug; 2(8):e693. PubMed ID: 17668070
[TBL] [Abstract][Full Text] [Related]
4. Molecular modes of action of artesunate in tumor cell lines.
Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
[TBL] [Abstract][Full Text] [Related]
5. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether.
Efferth T; Olbrich A; Bauer R
Biochem Pharmacol; 2002 Aug; 64(4):617-23. PubMed ID: 12167480
[TBL] [Abstract][Full Text] [Related]
6. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside.
Efferth T
Planta Med; 2007 Apr; 73(4):299-309. PubMed ID: 17354163
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.
Efferth T; Ramirez T; Gebhart E; Halatsch ME
Biochem Pharmacol; 2004 May; 67(9):1689-700. PubMed ID: 15081868
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Chen HH; Zhou HJ; Wu GD; Lou XE
Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
[TBL] [Abstract][Full Text] [Related]
9. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71.
Zhao F; Wang H; Kunda P; Chen X; Liu QL; Liu T
Oncol Rep; 2013 Sep; 30(3):1473-82. PubMed ID: 23818062
[TBL] [Abstract][Full Text] [Related]
10. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell.
Huan-huan C; Li-Li Y; Shang-Bin L
Cancer Lett; 2004 Aug; 211(2):163-73. PubMed ID: 15219940
[TBL] [Abstract][Full Text] [Related]
11. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
Greenshields AL; Fernando W; Hoskin DW
Exp Mol Pathol; 2019 Apr; 107():10-22. PubMed ID: 30660598
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.
Efferth T
Drug Resist Updat; 2005; 8(1-2):85-97. PubMed ID: 15878303
[TBL] [Abstract][Full Text] [Related]
13. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate.
Greenshields AL; Shepherd TG; Hoskin DW
Mol Carcinog; 2017 Jan; 56(1):75-93. PubMed ID: 26878598
[TBL] [Abstract][Full Text] [Related]
14. High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.
Tyagi RK; Gleeson PJ; Arnold L; Tahar R; Prieur E; Decosterd L; Pérignon JL; Olliaro P; Druilhe P
BMC Med; 2018 Oct; 16(1):181. PubMed ID: 30269689
[TBL] [Abstract][Full Text] [Related]
15. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
16. Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
Sertel S; Eichhorn T; Sieber S; Sauer A; Weiss J; Plinkert PK; Efferth T
Chem Biol Interact; 2010 Apr; 185(1):42-52. PubMed ID: 20144594
[TBL] [Abstract][Full Text] [Related]
17. Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines.
Liu Y; Cui YF
Asian Pac J Cancer Prev; 2013; 14(9):5243-8. PubMed ID: 24175808
[TBL] [Abstract][Full Text] [Related]
18. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.
Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D
Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352
[TBL] [Abstract][Full Text] [Related]
19. Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.
Aguiar AC; Pereira DB; Amaral NS; De Marco L; Krettli AU
Malar J; 2014 Feb; 13():73. PubMed ID: 24581308
[TBL] [Abstract][Full Text] [Related]
20. Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Berger TG; Dieckmann D; Efferth T; Schultz ES; Funk JO; Baur A; Schuler G
Oncol Rep; 2005 Dec; 14(6):1599-603. PubMed ID: 16273263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
